文献速递甲状腺疾病

雄激素受体抑制性miR-146b表达在甲状腺乳头状癌侵袭性中的临床影响

Clinical Impact of Androgen Receptor-Suppressing miR-146b Expression in Papillary Thyroid Cancer Aggressiveness.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

该研究探讨miR-146b作为雄激素受体(AR)潜在靶miRNA及其与甲状腺乳头状癌(PTC)侵袭性特征的关系。在PTC及癌旁正常甲状腺组织中检测AR与miR-146b表达并分析相关性,利用BCPAP和TPC-1细胞评估AR对miR-146b信号的影响,ChIP实验检测AR是否结合miR-146b启动子区。结果显示miR-146b与AR表达呈显著负相关,AR过表达细胞miR-146b表达较低,AR可能结合miR-146b基因启动子区的雄激素受体元件并抑制miR-146b介导的肿瘤侵袭性;低AR/高miR-146b组与更高肿瘤分期、淋巴结转移和更差治疗反应相关。结论:miR-146b是AR转录抑制的分子靶点,AR通过抑制miR-146b表达降低PTC肿瘤侵袭性。

要点

  • miR-146b与AR表达呈显著负相关。
  • AR过表达的BCPAP和TPC-1细胞miR-146b表达相对较低。
  • 低AR/高miR-146b组与更高肿瘤分期、淋巴结转移和更差治疗反应相关。

核心结论

  • miR-146b是AR转录抑制的分子靶点,AR通过抑制miR-146b表达降低PTC肿瘤侵袭性。

研究设计与样本

  • 在PTC及癌旁正常甲状腺冷冻和福尔马林固定石蜡包埋组织中用定量实时聚合酶链反应检测AR与miR-146b表达并分析相关性。
  • 使用人甲状腺癌细胞系BCPAP和TPC-1评估AR对miR-146b信号的影响。
  • 采用染色质免疫沉淀(ChIP)实验检测AR是否结合miR-146b启动子区。

主要发现

  • Pearson相关分析证实miR-146b与AR表达呈显著负相关。
  • 过表达AR的BCPAP和TPC-1细胞显示相对较低的miR-146b表达。
  • ChIP实验显示AR可能结合位于miRNA-146b基因启动子区的雄激素受体元件。
  • AR过表达抑制miR-146b介导的肿瘤侵袭性。
  • 低AR/高miR-146b的PTC患者组与更高肿瘤分期、淋巴结转移和更差治疗反应等侵袭性特征相关。

关键数值与推荐

  • miR-146b与AR表达呈显著负相关(Pearson相关分析)。
  • 过表达AR的BCPAP和TPC-1细胞miR-146b表达相对较低。
  • 低AR/高miR-146b组与更高肿瘤分期、淋巴结转移和更差治疗反应相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Papillary thyroid carcinoma (PTC) is the most common thyroid malignancy. Dysregulated expression of miR-146b and androgen receptor (AR) has been shown to play critical roles in tumorigenesis in PTC. However, the mechanistic and clinical association between AR and miR-146b is not fully understood. OBJECTIVE: The purpose was to investigate miR-146b as the potential AR target miRNA and its involvement in advanced tumor characteristics of PTC. METHODS: Expression of AR and miR-146b were assessed in frozen and formalin-fixed paraffin-embedded tissue samples from PTC and adjacent normal thyroid specimens by quantitative real-time polymerase chain reaction, and their correlation was examined. Human thyroid cancer cell lines BCPAP and TPC-1 were used to evaluate the effect of AR on miR-146b signaling. Chromatin immunoprecipitation (ChIP) assays were performed to determine whether AR binds to the miR-146b promoter region. RESULTS: Pearson correlation analysis confirmed significant inverse correlation between miR-146b and AR expression. Overexpressing AR BCPAP and TPC-1 cells showed relatively lower miR-146b expression. ChIP assay revealed that AR might bind to the androgen receptor element located on the promoter region of miRNA-146b gene, and overexpression of AR suppresses miR-146b-mediated tumor aggressiveness. The low AR/high miR-146b PTC patient group was associated with advanced tumor characteristics, including higher tumor stage, lymph node metastasis, and worse treatment response. CONCLUSION: To sum up, miR-146b is a molecular target of AR transcriptional repression; therefore, AR suppresses miR-146b expression to reduce PTC tumor aggressiveness.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Chou CK, Chi SY, Hung YY, et al. Clinical Impact of Androgen Receptor-Suppressing miR-146b Expression in Papillary Thyroid Cancer Aggressiveness. J Clin Endocrinol Metab. 2023. PMID: 37220080. doi:10.1210/clinem/dgad279

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。